Last reviewed · How we verify
ABBV-399
ABBV-399 is a PD-1 inhibitor, a type of immunotherapy that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells more effectively.
ABBV-399 is a PD-1 inhibitor, a type of immunotherapy that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells more effectively. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | ABBV-399 |
|---|---|
| Sponsor | SWOG Cancer Research Network |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By blocking the PD-1 receptor, ABBV-399 allows T cells to recognize and attack cancer cells more effectively, leading to an enhanced anti-tumor response. This mechanism is thought to be responsible for the drug's ability to treat various types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Expanded Access to Telisotuzumab Vedotin
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (PHASE2)
- Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (PHASE2)
- A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors (PHASE1)
- A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-399 CI brief — competitive landscape report
- ABBV-399 updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI